Monday, January 24, 2011
The public, and FDA
itself, would benefit from smart, focused congressional oversight over the
agency. Unfortunately, House Republicans have gotten off to a bad start,
leveling unsubstantiated allegations against FDA and exploiting a controversial
regulatory decision to advance a political agenda.
As chair of the Energy and
Commerce Committee, Rep. Fred Upton (R-Mich.) is the most important voice in
Congress when it comes to FDA. That's why his first comments on the agency's
decision to remove the first-line metastatic breast cancer indication from
Avastin bevacizumab are especially disappointing.